Known targets — ChEMBL curated mechanism
DRD4HTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3E
The experimentally established mechanism targets of Clothiapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 1.00 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 1.00 |
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 6/20 | 0.62 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.55 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.55 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.55 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 11/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 4/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clothiapine SCHEMBL29360219 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD3HRH1DRD1 | |
| Clothiapine SCHEMBL27848972 | 0.87 | DRD2 (0.76) | DRD2CHRM1DRD3HRH1DRD1 | |
| Metiapine SCHEMBL29710898 | 0.86 | DRD2 (0.76) | DRD2CHRM1DRD3HRH1DRD1 | |
| Metiapine SCHEMBL121263 | 0.86 | DRD2 (0.76) | DRD2CHRM1DRD3HRH1DRD1 | |
| SCHEMBL144624 | 0.86 | DRD2 (0.74) | DRD2CHRM1DRD3HRH1DRD1 | |
| SCHEMBL9377234 | 0.85 | DRD2 (1.00) | DRD2CHRM1DRD3HRH1DRD1 | |
| SCHEMBL14631841 | 0.85 | DRD2 (1.00) | DRD2CHRM1DRD3HRH1DRD1 | |
| SCHEMBL7403485 | 0.85 | DRD2 (0.74) | DRD2CHRM1DRD3HRH1DRD1 | |
| SCHEMBL9211771 | 0.84 | DRD2 (0.72) | DRD2CHRM1DRD3HRH1DRD1 | |
| SCHEMBL9094940 | 0.83 | DRD2 (0.72) | DRD2CHRM1DRD3HRH1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2524 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | claimed |
| WO-2025080415-A1 | TREATMENT OF NEUROPSYCHIATRIC DISORDERS WITH TILIVAPRAM | ALTO NEUROSCIENCE, INC. (US) | 2025-04-17 | — | — | WO | claimed |
| US-20250120957-A1 | TREATMENT OF NEUROPSYCHIATRIC DISORDERS WITH TILIVAPRAM | ALTO NEUROSCIENCE, INC. | 2025-04-17 | — | — | US | claimed |
| WO-2024107681-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| US-20240000810-A1 | USE OF CANNABINOIDS IN THE TREATMENT OF TOURETTE SYNDROME AND TIC DISORDERS | Orcosa Inc. (US) | 2024-01-04 | — | — | US | claimed |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-10-12 | — | — | US | claimed |
| US-20230218623-A1 | SALTS OF NEUROCEUTICALS AND USES THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2023-07-13 | — | — | US | claimed |
| EP-4192579-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-06-14 | — | — | EP | claimed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0772442-A1 | USE OF IMMUNOSUPPRESSIVE AGENTS FOR THE TREATMENT OF SCHIZOPHRENIA | YEDA RESEARCH & DEVELOPMENT COMPANY, LTD. (IL) | 1997-05-14 | — | — | EP | claimed |
| WO-1995034306-A1 | USE OF IMMUNOSUPPRESSIVE AGENTS FOR THE TREATMENT OF SCHIZOPHRENIA | YEDA RESEARCH AND DEVELOPMENT CO., LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE (IL) | 1995-12-21 | — | — | WO | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
| EP-0174342-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES. | UNIV FLORIDA (US) | 1986-03-19 | — | — | EP | claimed |
| WO-1985003937-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1985-09-12 | — | — | WO | claimed |